Gilead Sciences (GILD) Upgraded to Hold at ValuEngine

ValuEngine upgraded shares of Gilead Sciences (NASDAQ:GILD) from a sell rating to a hold rating in a report published on Saturday morning.

A number of other research firms have also commented on GILD. Raymond James restated a buy rating on shares of Gilead Sciences in a research report on Thursday, November 1st. BidaskClub lowered shares of Gilead Sciences from a buy rating to a hold rating in a research report on Wednesday, October 24th. Piper Jaffray Companies lowered shares of Gilead Sciences from an overweight rating to a neutral rating and reduced their price target for the company from $85.00 to $75.00 in a research report on Friday, October 26th. Evercore ISI restated a buy rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Monday, October 1st. They issued an overweight rating and a $87.00 price target on the stock. Twelve analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of Buy and an average price target of $88.63.

NASDAQ:GILD opened at $71.94 on Friday. The stock has a market capitalization of $93.06 billion, a price-to-earnings ratio of 8.40, a PEG ratio of -2.79 and a beta of 1.01. Gilead Sciences has a 12 month low of $64.27 and a 12 month high of $89.54. The company has a current ratio of 3.45, a quick ratio of 3.37 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.21. The firm had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the previous year, the business earned $2.27 earnings per share. Research analysts predict that Gilead Sciences will post 6.44 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders have sold 150,000 shares of company stock valued at $11,087,500. 1.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of GILD. Resource Management LLC grew its holdings in Gilead Sciences by 6.7% during the second quarter. Resource Management LLC now owns 10,688 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 674 shares during the period. Stralem & Co. Inc. boosted its holdings in shares of Gilead Sciences by 8.0% in the third quarter. Stralem & Co. Inc. now owns 9,400 shares of the biopharmaceutical company’s stock valued at $726,000 after buying an additional 700 shares during the period. Silverleafe Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 17.4% in the third quarter. Silverleafe Capital Partners LLC now owns 4,719 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 701 shares during the period. Reilly Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 98.3% in the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares during the period. Finally, Kornitzer Capital Management Inc. KS boosted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Kornitzer Capital Management Inc. KS now owns 174,000 shares of the biopharmaceutical company’s stock valued at $12,326,000 after buying an additional 710 shares during the period. 77.57% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: How mutual funds make money

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit